Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424528 · ClinicalTrials.gov registry record · Phase 4
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 4 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 4
- Development phase
- 235
- Enrollment target
NCT00424528 is a Phase 4 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 235 participants.
The verdict
NCT00424528, a Phase 4 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).
Interventions
- DRUG Placebo
- DRUG Tiotropium
- DRUG Arformoterol Tartrate Inhalation Solution
- DRUG Arformoterol and Tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424528
The ClinicalTrials.gov registry entry for NCT00424528 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00424528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424528 about?
NCT00424528 is a clinical study titled "Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT00424528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 235 participants. The study started on 2006-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00424528?
The interventions under investigation include: Placebo (DRUG), Tiotropium (DRUG), Arformoterol Tartrate Inhalation Solution (DRUG), Arformoterol and Tiotropium (DRUG).
Who is sponsoring clinical trial NCT00424528?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.